- Stocks
- Healthcare
- NASDAQ: AVDL

Price (delayed)

$7.85

Market cap

$459.13M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.09

Enterprise value

$543.62M

AVDL's quick ratio has surged by 53% since the previous quarter

Avadel Pharmaceuticals's net income has plunged by 179% from the previous quarter but it has soared by 74% YoY

Avadel Pharmaceuticals's EPS has shrunk by 169% QoQ but it has surged by 84% YoY

The gross profit has shrunk by 84% YoY and by 59% QoQ

The revenue has plunged by 82% YoY and by 55% from the previous quarter

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Website: https://www.avadel.com/

What are the main financial stats of AVDL

Market
Valuations
Earnings

Shares outstanding

58.49M

Market cap

$459.13M

Enterprise value

$543.62M

Price to earnings (P/E)

N/A

Price to book (P/B)

3.36

Price to sales (P/S)

45.46

EV/EBIT

558.13

EV/EBITDA

224.08

EV/Sales

53.87

Revenue

$10.09M

EBIT

$974,000

EBITDA

$2.43M

Free cash flow

-$60.64M

Per share
Balance sheet
Liquidity

EPS

-$0.09

Free cash flow per share

-$1.04

Book value per share

$2.33

Revenue per share

$0.17

TBVPS

$4.72

Total assets

$292.94M

Total liabilities

$156.44M

Debt

$143.66M

Equity

$136.5M

Working capital

$233.19M

Debt to equity

1.05

Current ratio

26.57

Quick ratio

22.48

Net debt/EBITDA

34.83

Margins
Efficiency
Dividend

EBITDA margin

24%

Gross margin

67.4%

Net margin

-55%

Operating margin

-16.4%

Return on assets

-1.7%

Return on equity

-3.4%

Return on invested capital

0.3%

Return on capital employed

0.3%

Return on sales

9.7%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Avadel Pharmaceuticals stock price performed over time

Intraday

0%

1 week

2.21%

1 month

6.8%

1 year

-10.49%

YTD

17.51%

QTD

-13.16%

How have Avadel Pharmaceuticals's revenue and profit performed over time

Revenue

$10.09M

Gross profit

$6.81M

Operating income

-$1.65M

Net income

-$5.55M

Gross margin

67.4%

Net margin

-55%

Avadel Pharmaceuticals's net income has plunged by 179% from the previous quarter but it has soared by 74% YoY

AVDL's operating margin has shrunk by 140% QoQ but it has soared by 58% YoY

The company's operating income has shrunk by 118% QoQ but it has surged by 92% YoY

The gross profit has shrunk by 84% YoY and by 59% QoQ

What is Avadel Pharmaceuticals's growth rate over time

What is Avadel Pharmaceuticals stock price valuation

P/E

N/A

P/B

3.36

P/S

45.46

EV/EBIT

558.13

EV/EBITDA

224.08

EV/Sales

53.87

Avadel Pharmaceuticals's EPS has shrunk by 169% QoQ but it has surged by 84% YoY

The stock's price to book (P/B) is 55% less than its 5-year quarterly average of 7.4 but 29% more than its last 4 quarters average of 2.6

The company's equity fell by 16% QoQ

The price to sales (P/S) is 110% higher than the last 4 quarters average of 21.6

The revenue has plunged by 82% YoY and by 55% from the previous quarter

How efficient is Avadel Pharmaceuticals business performance

AVDL's return on assets has dropped by 171% since the previous quarter but it has surged by 86% year-on-year

The ROE has plunged by 167% from the previous quarter

Avadel Pharmaceuticals's return on sales has surged by 123% YoY but it has shrunk by 73% QoQ

The ROIC has soared by 103% YoY but it has plunged by 88% from the previous quarter

What is AVDL's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for AVDL.

How did Avadel Pharmaceuticals financials performed over time

The total assets is 87% more than the total liabilities

AVDL's quick ratio has surged by 53% since the previous quarter

Avadel Pharmaceuticals's current ratio has soared by 52% from the previous quarter

The debt is 5% greater than the equity

Avadel Pharmaceuticals's debt to equity has plunged by 73% YoY but it has increased by 31% from the previous quarter

The company's equity fell by 16% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.